Baicalin-7-glucoside (Oroxin A) exhibits a range of pharmacological activities, including anti-inflammatory, antibacterial, antioxidant, anti-mutagenic, antitussive, expectorant, anticancer, and anti-cataract effects; it also demonstrates cytotoxicity against various cancer cell lines such as leukemia, acute myeloid leukemia, melanoma, colon cancer, and human breast cancer cells (MCF7 and MDA-MB-231); additionally, it shows potential in alleviating gastric mucosal DNA damage and promoting cell proliferation in experimental models.